Avidigo services
White glove Cell Avidity services
Full-service contract research from experimental design to data report based on Cell Avidity measurements at high throughput.
Part of:
The perfect Cell Avidity pilot study and a potential stepping stone to an Avidion
Make use of an expert team, from catered experimental design to data interpretation
Gain access to Cell Avidity data within a rapid timeframe
Typical timeframe
What's powering my experiments?
Avidion
The next generation Cell Avidity platform
With its high throughput capabilities, easy to use workflow and broad set of applications, our Avidigo services exclusively use our Avidion technology.
Key content
Discover all the details
Avidigo Service Brochure
Brochure
The latest all-in-one overview of our Avidigo solution.
Let’s get in touch
Our team is standing by to help you
Technical note:
Filter CA shows 3 items
There is a hidden collection to add multiple authors to this publication.
This section is hidden when emtpy.
To keep everything visible here, that is being done outside the webflow designer from within Slater.
Filter CA shows 3 items
There is a hidden collection to add multiple authors to this publication.
This section is hidden when emtpy.
To keep everything visible here, that is being done outside the webflow designer from within Slater.
Text Link
Identification of potent biparatopic antibodies targeting FGFR2 fusion driven cholangiocarcinoma
Chaturantabut, S. et al.
2025
J. Clin. Investigation
https://www.jci.org/articles/view/182417
Publication
Text Link
Rational Chemical and Genetic Modifications Enhance Avidity and Function of CD70-Directed CAR T Cells for Myeloid Leukemia
Leick, M. B. et al.
2022
Cancer Cell
https://doi.org/10.1016/j.ccell.2022.04.001
Publication
Technical note:
Filter CA and show 4 Latest
This shows the most recent card of each resource type filtered on Business Unit CA.
Webinar, Scientific update, Whitepaper, Application note, Brochure.
We only show 4 and we have 6 types so the 2 older ones are hidden.
In design only 1 is shown, but the rest will be loaded when published.
Filter CA and show 4 Latest
This shows the most recent card of each resource type filtered on Business Unit CA.
Webinar, Scientific update, Whitepaper, Application note, Brochure.
We only show 4 and we have 6 types so the 2 older ones are hidden.
In design only 1 is shown, but the rest will be loaded when published.
Button Text
Improving CAR-T immunotherapy for lymphoma by fine-tuning avidity
Webinar
July 16, 2024
01-01-20
Commercial CAR-T therapies still suffer from severe limitations, as majority of patients fail to achieve complete response and ultimately relapse.
Watch this Webinar to discover Prof. Marco Ruella’s team have adopted a novel CAR-T avidity screening method to improve safety and exhaustion profile, leading to 100% clinical response in a phase I trial.
Text Link
Enhancing efficacy against clear cell renal cell carcinoma through format-tuning of bispecific T cell engagers
Scientific update
January 29, 2025
01-01-20
Cell Avidity: a key to accelerate IND filing in cell therapy drug development
Whitepaper
July 1, 2023
01-01-20
Cell Avidity measures true binding of biparatopic antibodies
Application note
April 23, 2025
01-01-20
Mechanistic issues limit the effectiveness of many current cancer-targeting antibody therapies, with monospecific antibodies often hindered by receptor dimerization and activation. Biparatopic antibodies, which bind to two unique non-overlapping epitopes, offer a promising solution with stronger binding, more potent antagonism, and higher specificity.
Avidigo Service Brochure
Brochure
May 1, 2025
01-01-20
SITC 2025
Conference
April 22, 2025
01-01-20
CAR-TCR Summit 2025
Conference
April 22, 2025
01-01-20
CICON 2025
Conference
April 22, 2025
01-01-20
See more. Know more.
We empower the academic and pharmaceutical communities with cutting-edge technologies to deeply understand the mechanisms of life and disease, driving the discovery and development of life-saving therapies
All products and technologies are for Research Use Only (RUO) except when specifically noted